We subsequently extended these earlier findings to a model in which anti-EMT6 tumor immunity was explored in CD200-/- mice and CD200R-/- receiving immunotherapy (with irradiated tumor cells and CpG as adjuvant) following surgical resection of tumor [4]. This evidence concerns the gene CD200R1 and neoplasm.